Developer docs
API playgroundTry for free, no card

Search company profiles

Metabogen

Full company profile

uuid0004zd6

Namestring
Metabogen
Legal namestring
BioGaia AB (publ)
Websiteurl
metabogen.se
Company typeenum
Public
Founded yearint
1990
Descriptiontext

Metabogen is a Stockholm-based R&D company founded in 2011 that is building capabilities in microbiome-derived biomarkers and personalized treatment services. The company was co-founded by Fredrik Bäckhed, a recognized microbiome researcher, and is led by CEO Sara Malcus. Metabogen's scientific positioning sits within the Swedish microbiome research ecosystem, with operational links to BioGaia's L. reuteri probiotic research platform spanning more than 35 years and 290 published clinical studies.

Metabogen's development model centers on translating microbiome and metabolomics research into biomarker signatures and personalized therapeutic applications, distinguishing it from a commercial probiotics manufacturer. Strategic validation has come through two disclosed capital events: a non-dilutive grant of approximately $596K from Vinnova in October 2017, and a strategic investment of approximately $1.39M from BioGaia in April 2018. The BioGaia investment in particular indicates alignment between Metabogen's biomarker R&D roadmap and a large affiliated probiotics franchise with distribution reach across 100 countries.

The company's commercial stage remains early and pre-revenue: no product launches, pricing, or named customer contracts are disclosed in the available data, and the cumulative disclosed capital base is approximately $2M. Metabogen operates as a private Swedish firm. The firmographic headcount band of 51-100 employees is inconsistent with the disclosed capital base and likely reflects data confusion with affiliated BioGaia records; this discrepancy should be flagged for due-diligence verification before any investment decision.

Short descriptiontext

Metabogen is a Stockholm-based private R&D company founded in 2011 that develops microbiome-derived biomarkers and personalized treatment services. Co-founded by microbiome researcher Fredrik Bäckhed and led by CEO Sara Malcus, it operates within the Swedish microbiome research ecosystem with strategic backing from BioGaia and Vinnova.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMölndal, Sweden
HQ citystring
Mölndal
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
biomarker discovery, personalized medicine, microbiome research, gut microbiome analysis, metagenomic sequencing
Industry3 codes
PRIMARYHLAAAFAH
Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal)
SECONDARYHLAAAFAI
Microbiome Analytics, Sequencing & Bioinformatics Platforms
SECONDARYHLAGANAH
Microbiome & Metagenomics Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical Laboratories621511
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
Product category
Microbiome Biomarker Services
Social media profiles1 record
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1BioGaia Skincare
Description

Skincare product line for babies and children developed by subsidiary Biogaia New Sciences AB, applying microbiome expertise to support healthy and balanced skin.

biogaiagroup.com
+1 more record
Core offering1 text field

Metabogen operates a research and development company intended to offer biomarker and personalized treatment services, with core scientific work grounded in microbiome research and Lactobacillus reuteri (L. reuteri) strain science that has been developed for over 35 years. The company develops biomarker-based methods and personalized therapeutic approaches, leveraging one of the most scientifically documented probiotic strain libraries in the world, supported by 290+ published clinical studies. Customers are expected to be pharmaceutical, clinical, and research organizations seeking microbiome-based diagnostics and treatment stratification.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • One out of five families globally wake up every night due to colicky babies - BioGaia Protectis Plus developed to address this
Product overview1 text field

BioGaia is a Swedish world-leading probiotics company that has been at the forefront of microbiome research for over 35 years. The company develops, manufactures, markets, and sells probiotic products across three main health areas: gut health, immune health, and oral health. The core product portfolio centers on probiotic products with strains of L. reuteri, which are among the most scientifically documented in the world with 290 published studies. The company also operates subsidiary Biogaia New Sciences AB, which has expanded into BioGaia® Skincare products for babies and children. Recent product launches include BioGaia® Protectis® Plus (next-generation probiotic baby drops) and an expanded BioGaia® Skincare portfolio.

Product and service2 records
1Biomarker Discovery Services
CategoryMicrobiome Biomarker R&D Services
Description

R&D services identifying and validating microbiome-derived biomarkers intended for use in research and clinical applications by pharmaceutical, clinical, and research customers.

2Personalized Treatment Services
CategoryPersonalized Medicine Services
Description

Personalized treatment services leveraging microbiome science and Lactobacillus reuteri strain research to support patient stratification and tailored therapeutic recommendations for clinical and research partners.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Metabogen

Microbiome Biomarker Servicesmetabogen.se

Metabogen is a Stockholm-based private R&D company founded in 2011 that develops microbiome-derived biomarkers and personalized treatment services. Co-founded by microbiome researcher Fredrik Bäckhed and led by CEO Sara Malcus, it operates within the Swedish microbiome research ecosystem with strategic backing from BioGaia and Vinnova.

What Metabogen does

Metabogen is a Stockholm-based R&D company founded in 2011 that is building capabilities in microbiome-derived biomarkers and personalized treatment services. The company was co-founded by Fredrik Bäckhed, a recognized microbiome researcher, and is led by CEO Sara Malcus. Metabogen's scientific positioning sits within the Swedish microbiome research ecosystem, with operational links to BioGaia's L. reuteri probiotic research platform spanning more than 35 years and 290 published clinical studies.

Metabogen's development model centers on translating microbiome and metabolomics research into biomarker signatures and personalized therapeutic applications, distinguishing it from a commercial probiotics manufacturer. Strategic validation has come through two disclosed capital events: a non-dilutive grant of approximately $596K from Vinnova in October 2017, and a strategic investment of approximately $1.39M from BioGaia in April 2018. The BioGaia investment in particular indicates alignment between Metabogen's biomarker R&D roadmap and a large affiliated probiotics franchise with distribution reach across 100 countries.

The company's commercial stage remains early and pre-revenue: no product launches, pricing, or named customer contracts are disclosed in the available data, and the cumulative disclosed capital base is approximately $2M. Metabogen operates as a private Swedish firm. The firmographic headcount band of 51-100 employees is inconsistent with the disclosed capital base and likely reflects data confusion with affiliated BioGaia records; this discrepancy should be flagged for due-diligence verification before any investment decision.

Metabogen firmographics

Firmographics
Name
Metabogen
Legal name
BioGaia AB (publ)
Website
https://metabogen.se
Company type
Public
Founded year
1990
Operating status
Operating
Headcount range
1–10 employees
Short description
Metabogen is a Stockholm-based private R&D company founded in 2011 that develops microbiome-derived biomarkers and personalized treatment services. Co-founded by microbiome researcher Fredrik Bäckhed and led by CEO Sara Malcus, it operates within the Swedish microbiome research ecosystem with strategic backing from BioGaia and Vinnova.
Ownership category
akta.pro rank

Metabogen industry classification

Industry
Product category
Microbiome Biomarker Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511), Scientific Research and Development Services (5417)
SIC
Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAFAH
Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal)
SECONDARYHLAAAFAI
Microbiome Analytics, Sequencing & Bioinformatics Platforms
SECONDARYHLAGANAH
Microbiome & Metagenomics Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)

Keywords

  • Biomarker discovery
  • Personalized medicine
  • Microbiome research
  • Gut microbiome analysis
  • Metagenomic sequencing

Where Metabogen is headquartered

Location

Headquarters

HQ city
Mölndal
HQ country
Sweden
HQ region
Europe

Markets served

Metabogen business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Distribution channels2 records

Marketing channels3 records

Metabogen product offering

Product offering

Core offering

Metabogen operates a research and development company intended to offer biomarker and personalized treatment services, with core scientific work grounded in microbiome research and Lactobacillus reuteri (L. reuteri) strain science that has been developed for over 35 years. The company develops biomarker-based methods and personalized therapeutic approaches, leveraging one of the most scientifically documented probiotic strain libraries in the world, supported by 290+ published clinical studies. Customers are expected to be pharmaceutical, clinical, and research organizations seeking microbiome-based diagnostics and treatment stratification.

Product overview

BioGaia is a Swedish world-leading probiotics company that has been at the forefront of microbiome research for over 35 years. The company develops, manufactures, markets, and sells probiotic products across three main health areas: gut health, immune health, and oral health. The core product portfolio centers on probiotic products with strains of L. reuteri, which are among the most scientifically documented in the world with 290 published studies. The company also operates subsidiary Biogaia New Sciences AB, which has expanded into BioGaia® Skincare products for babies and children. Recent product launches include BioGaia® Protectis® Plus (next-generation probiotic baby drops) and an expanded BioGaia® Skincare portfolio.

Differentiator

Problem solved

Functional benefit

Brands

  • BioGaia Skincare: Skincare product line for babies and children developed by subsidiary Biogaia New Sciences AB, applying microbiome expertise to support healthy and balanced skin.
  • BioGaia Protectis Plus

Products and services

  • Biomarker Discovery Services R&D services identifying and validating microbiome-derived biomarkers intended for use in research and clinical applications by pharmaceutical, clinical, and research customers.
  • Personalized Treatment Services Personalized treatment services leveraging microbiome science and Lactobacillus reuteri strain research to support patient stratification and tailored therapeutic recommendations for clinical and research partners.

Quantifiable outcome

  • One out of five families globally wake up every night due to colicky babies - BioGaia Protectis Plus developed to address this

Companies that use Metabogen

Customer profile

Segments2 records

Ideal customer profiles1 record

Metabogen technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Metabogen partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves3 records

Expansion highlights4 records

Metabogen competitors and assessment

Company assessment

Market position

Strengths4 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

Metabogen social profiles

Digital presence

Metabogen compliance and trust

Trust signal

Compliance1 record

Metabogen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Metabogen leadership team

Management profile

Number of profiles

Profiles2 records

Metabogen subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Metabogen funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Metabogen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Metabogen

What does Metabogen do?

Metabogen operates a research and development company intended to offer biomarker and personalized treatment services, with core scientific work grounded in microbiome research and Lactobacillus reuteri (L. reuteri) strain science that has been developed for over 35 years. The company develops biomarker-based methods and personalized therapeutic approaches, leveraging one of the most scientifically documented probiotic strain libraries in the world, supported by 290+ published clinical studies. Customers are expected to be pharmaceutical, clinical, and research organizations seeking microbiome-based diagnostics and treatment stratification.

Is Metabogen a public or private company?

Metabogen is a public company. It is classified as venture growth investor backed and is currently operating.

When was Metabogen founded?

Metabogen was founded in 1990. It employs 1 to 10 people.

Where is Metabogen based?

Metabogen is headquartered in Mölndal, Sweden, in the Europe region.

Does Metabogen have an API?

No public API is recorded for Metabogen.

What industry is Metabogen in?

Metabogen's product category is Microbiome Biomarker Services. Its primary akta.pro industry code is HLAAAFAH, Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal), with a secondary code of HLAAAFAI, Microbiome Analytics, Sequencing & Bioinformatics Platforms. Its NAICS code is 541714 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals